|
Volumn 80, Issue 3, 2001, Pages B73-B76
|
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy
|
Author keywords
Childhood; Lymphoblastic lymphoma; T cell; Therapy
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ASPARAGINASE;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DAUNORUBICIN;
DEXAMETHASONE;
DOXORUBICIN;
MERCAPTOPURINE;
METHOTREXATE;
PREDNISONE;
TIOGUANINE;
VINCRISTINE;
ADOLESCENT;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CHILD;
CHILDHOOD CANCER;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOSE TIME EFFECT RELATION;
DRUG MEGADOSE;
FEMALE;
FOLLOW UP;
HUMAN;
LYMPHOBLASTOMA;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
PRIORITY JOURNAL;
PROGNOSIS;
SURVIVAL RATE;
T CELL LYMPHOMA;
TREATMENT OUTCOME;
TUMOR REGRESSION;
6-MERCAPTOPURINE;
ADOLESCENT;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASPARAGINASE;
AUSTRIA;
CHILD;
CHILD, PRESCHOOL;
COMBINED MODALITY THERAPY;
CRANIAL IRRADIATION;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DAUNORUBICIN;
DEXAMETHASONE;
DISEASE-FREE SURVIVAL;
DOXORUBICIN;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
GERMANY;
HUMANS;
IMMUNOPHENOTYPING;
INFANT;
LIFE TABLES;
LYMPHOMA, LYMPHOBLASTIC;
LYMPHOMA, T-CELL;
MALE;
METHOTREXATE;
NEOPLASM STAGING;
PREDNISONE;
RADIOTHERAPY, ADJUVANT;
REMISSION INDUCTION;
THIOGUANINE;
TREATMENT OUTCOME;
VINCRISTINE;
|
EID: 0035204437
PISSN: 09458077
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (24)
|
References (20)
|